ERBB2 and breast carcinoma: The phase III BROCADE3 trial compared veliparib plus carboplatin plus paclitaxel versus placebo combined with carboplatin and paclitaxel in patients with HER2-negative advanced breast cancer and a germline BRCA1 or BRCA2 mutation (NCT02163694) [87].